First C3 CellSpray XP patient treated

The first patient has been treated with Clinical Cell Culture's (C3, ASX:CCE) CellSpray XP at Dortmund Hospital in Germany.

CellSpray XP is a 48-hour harvest autologous cell suspension for use in the treatment of patients with burn or scar injuries of 10 per cent to 30 per cent of the body surface. The product now has European regulatory approval in Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK and is available for sale in these countries.

C3 will receive revenue of AUD$40,000 from the first use of CellSpray XP and future sales will provide the company with a third commercial revenue stream, in addition to existing sales of ReCell in Japan and confirmed stocking orders for ReCell in Europe.

ReCell is an autologous cell harvesting device that uses collected healthy skin cells for immediate application on damaged skin such as small burns, areas of pigment loss, and scars.

CellSpray XP's sister product, CellSpray, is scheduled for launch in September. Cell Spray is intended for use in patients with between 30 per cent and 90 per cent of injuries to the body surface.